source
- Novartis withdraws EU filing for Pluvicto label expansion into early-stage prostate cancerNovartis announced it has pulled its application to the European Medicines Agency to extend the label of its radioligand therapy Pluvicto for use in earlier stages of prostate cancer. The move com…
- FDA grants fast-track vouchers to three psychedelic firmsThe FDA announced it has issued fast-track development vouchers to three companies working on psychedelic therapies. The recipients are R&DCompass, Transcend, and the Usona Institute. The vouchers…